Actively Recruiting
Single-cell Multi-omics Analyses of OCT-diagnosed Plaque Subtypes in Coronary Artery Disease (MOOP-CAD)
Led by Harbin Medical University · Updated on 2025-09-15
350
Participants Needed
2
Research Sites
105 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The MOOP-CAD study program characterizes, for the first time, the pathophysiological processes and molecular mechanisms of coronary atherosclerotic plaque progression by combining in vivo intravascular imaging techniques with circulating immune single-cell multi-omics analysis. In this study, the investigators evaluate the imaging characteristics of coronary plaques by optical coherence tomography (OCT) and invasive angiography, and study the correlation between plaque characteristics and the multi-omics immune characteristic profiles.
CONDITIONS
Official Title
Single-cell Multi-omics Analyses of OCT-diagnosed Plaque Subtypes in Coronary Artery Disease (MOOP-CAD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, Age 6 18 years and 4 85 years.
- Ability to understand the requirements of the study and to provide informed consent.
- Control group: Patients with coronary angiographic diameter stenosis <20%.
- Stable plaque group: Clinically stable for at least 6 months, at least 1 lesion with >50% stenosis in the target vessel without TCFA lesions, no elevation of troponin or myocardial enzymes.
- Vulnerable plaque group: Clinically stable for at least 6 months, at least 1 lesion with >50% stenosis with TCFA lesions in the target vessel, no elevation of troponin or myocardial enzymes.
- Plaque rupture group: Persistent chest pain for 30 minutes, hospital arrival within 24 hours of symptom onset, ST-segment elevation >0.1 mV in 2 or more contiguous leads or new-onset left bundle branch block, elevated troponin or CK/CK-MB, clearly identified culprit lesion with plaque rupture.
- Plaque erosion group: Persistent chest pain for 30 minutes, hospital arrival within 24 hours of symptom onset, ST-segment elevation >0.1 mV in 2 or more contiguous leads or new-onset left bundle branch block, elevated troponin or CK/CK-MB, clearly identified culprit lesion with plaque erosion.
You will not qualify if you...
- Cardiogenic shock or circulatory depression, life-threatening arrhythmia.
- Known systolic heart failure with left ventricular ejection fraction (LVEF) 30%.
- Severe systemic diseases including end-stage renal disease, serious liver dysfunction, chronic active inflammatory diseases, active oncologic diseases, autoimmune diseases.
- Septicemia or acute inflammatory event with fever.
- Patients with organ transplants or waiting list for an organ transplant.
- Previous coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) of target or non-target vessels within 1 year.
- Thrombolysis before PCI.
- Stenosis of the left main artery 50%.
- Conditions preventing high-quality OCT imaging such as chronic total occlusion, severe vessel tortuosity, heavy calcification.
- Infarcted vessel diameter >4mm or <2.5mm.
- "No-reflow" with TIMI flow 0-1 after thrombus aspiration or predilatation.
- Other conditions deemed unsuitable by investigators.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
The Second Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China, 150081
Actively Recruiting
2
China-Japan Union Hospital of Jilin
Changchun, Jilin, China, 130033
Actively Recruiting
Research Team
B
Bo Yu, MD,PhD
CONTACT
M
Maomao Zhang, MD,PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here